Home > Publications Database > Brain Vascular Health in ALS Is Mediated through Motor Cortex Microvascular Integrity. > print

001     257330
005     20231120155338.0
024 7 _ |a 10.3390/cells12060957
|2 doi
024 7 _ |a pmid:36980297
|2 pmid
024 7 _ |a pmc:PMC10047140
|2 pmc
024 7 _ |a altmetric:144286063
|2 altmetric
037 _ _ |a DZNE-2023-00399
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Schreiber, Stefanie
|0 P:(DE-2719)2812631
|b 0
245 _ _ |a Brain Vascular Health in ALS Is Mediated through Motor Cortex Microvascular Integrity.
260 _ _ |a Basel
|c 2023
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1680772883_19772
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a CC BY
520 _ _ |a Brain vascular health appears to be critical for preventing the development of amyotrophic lateral sclerosis (ALS) and slowing its progression. ALS patients often demonstrate cardiovascular risk factors and commonly suffer from cerebrovascular disease, with evidence of pathological alterations in their small cerebral blood vessels. Impaired vascular brain health has detrimental effects on motor neurons: vascular endothelial growth factor levels are lowered in ALS, which can compromise endothelial cell formation and the integrity of the blood-brain barrier. Increased turnover of neurovascular unit cells precedes their senescence, which, together with pericyte alterations, further fosters the failure of toxic metabolite removal. We here provide a comprehensive overview of the pathogenesis of impaired brain vascular health in ALS and how novel magnetic resonance imaging techniques can aid its detection. In particular, we discuss vascular patterns of blood supply to the motor cortex with the number of branches from the anterior and middle cerebral arteries acting as a novel marker of resistance and resilience against downstream effects of vascular risk and events in ALS. We outline how certain interventions adapted to patient needs and capabilities have the potential to mechanistically target the brain microvasculature towards favorable motor cortex blood supply patterns. Through this strategy, we aim to guide novel approaches to ALS management and a better understanding of ALS pathophysiology.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 1
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 2
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a amyotrophic lateral sclerosis
|2 Other
650 _ 7 |a exerkines
|2 Other
650 _ 7 |a motor cortex
|2 Other
650 _ 7 |a pericytes
|2 Other
650 _ 7 |a vascular supply
|2 Other
650 _ 7 |a Vascular Endothelial Growth Factor A
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Amyotrophic Lateral Sclerosis: metabolism
|2 MeSH
650 _ 2 |a Motor Cortex: metabolism
|2 MeSH
650 _ 2 |a Vascular Endothelial Growth Factor A: metabolism
|2 MeSH
650 _ 2 |a Motor Neurons: pathology
|2 MeSH
650 _ 2 |a Blood-Brain Barrier: pathology
|2 MeSH
700 1 _ |a Bernal Moya, Jose
|0 P:(DE-2719)9001989
|b 1
|u dzne
700 1 _ |a Arndt, Philipp
|0 0000-0002-0517-6473
|b 2
700 1 _ |a Schreiber, Frank
|0 P:(DE-2719)9000986
|b 3
|u dzne
700 1 _ |a Müller, Patrick
|0 P:(DE-2719)2811487
|b 4
|u dzne
700 1 _ |a Morton, Lorena
|0 0000-0002-3957-3848
|b 5
700 1 _ |a Braun-Dullaeus, Rüdiger Christian
|b 6
700 1 _ |a Valdés-Hernández, Maria Del Carmen
|0 0000-0003-2771-6546
|b 7
700 1 _ |a Duarte, Roberto
|b 8
700 1 _ |a Wardlaw, Joanna Marguerite
|0 0000-0002-9812-6642
|b 9
700 1 _ |a Meuth, Sven Günther
|b 10
700 1 _ |a Mietzner, Grazia
|b 11
700 1 _ |a Vielhaber, Stefan
|0 P:(DE-2719)2000035
|b 12
|u dzne
700 1 _ |a Dunay, Ildiko Rita
|b 13
700 1 _ |a Dityatev, Alexander
|0 P:(DE-2719)2810577
|b 14
700 1 _ |a Jandke, Solveig
|0 P:(DE-2719)2813348
|b 15
|u dzne
700 1 _ |a Mattern, Hendrik
|0 P:(DE-2719)9002178
|b 16
|e Last author
|u dzne
770 _ _ |a Amyotrophic Lateral Sclerosis: Understanding the Pathogenetic Mechanisms for the Development of New Therapies
773 _ _ |a 10.3390/cells12060957
|g Vol. 12, no. 6, p. 957 -
|0 PERI:(DE-600)2661518-6
|n 6
|p 957
|t Cells
|v 12
|y 2023
|x 2073-4409
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/257330/files/DZNE-2023-00399.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/257330/files/DZNE-2023-00399.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:257330
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2812631
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9001989
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 0000-0002-0517-6473
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9000986
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2811487
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 12
|6 P:(DE-2719)2000035
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2810577
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 15
|6 P:(DE-2719)2813348
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 16
|6 P:(DE-2719)9002178
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 2
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-30
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-30
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2022-11-30
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2022-11-30
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-08-01T15:15:06Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-08-01T15:15:06Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-08-01T15:15:06Z
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CELLS-BASEL : 2022
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-26
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-26
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CELLS-BASEL : 2022
|d 2023-10-26
920 1 _ |0 I:(DE-2719)1310005
|k AG Reymann
|l Pathophysiology of Dementia
|x 0
920 1 _ |0 I:(DE-2719)1310010
|k AG Schreiber
|l Mixed Cerebral Pathologies and Cognitive Aging
|x 1
920 1 _ |0 I:(DE-2719)5000006
|k AG Düzel 3
|l Clinical Neurophysiology and Memory
|x 2
920 1 _ |0 I:(DE-2719)1310003
|k AG Müller
|l Neuroprotection
|x 3
920 1 _ |0 I:(DE-2719)1310007
|k AG Dityatev
|l Molecular Neuroplasticity
|x 4
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1310005
980 _ _ |a I:(DE-2719)1310010
980 _ _ |a I:(DE-2719)5000006
980 _ _ |a I:(DE-2719)1310003
980 _ _ |a I:(DE-2719)1310007
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21